TY - JOUR
T1 - SIX MONTHS TREATMENT WITH IBOPAMINE IN PATIENTS WITH HYPOTONY AFTER VITREORETINAL SURGERY FOR RETINAL DETACHMENT, UVEITIS OR PENETRATING TRAUMA
AU - Ganteris-Gerritsen, E
AU - Ugahary, LC
AU - Jansen, JTG (Jan)
AU - Mulder, PGH (Paul)
AU - Cohen, AF
AU - van Meurs, Johan
PY - 2012
Y1 - 2012
N2 - Purpose: To evaluate the effectiveness of 6 months treatment with ibopamine eye drops in raising the intraocular pressure in patients with therapy-resistant hypotony after vitreoretinal surgery for proliferative vitreoretinopathy secondary to rhegmatogenous retinal detachment or penetrating trauma. Methods: A 2% ibopamine eye drop was topically administered 3 times daily during 24 weeks. Results: Seventeen patients were included. Nine patients were able to continue their treatment up to 24 weeks; their mean intraocular pressure increase was 2.11 mmHg (SE, 0.56; 95% confidence interval, 0.96 to 3.23; P < 0.0005) in comparison with baseline values. Eight patients stopped using ibopamine before 24 weeks because of complains of follicular conjunctivitis or irritation without clinically observable conjunctivitis. In these patients a comparable increase in intraocular pressure was obs Conclusion: This study confirms that the use of topical ibopamine may result in a sustained increase in intraocular pressure of >2 mmHg in the majority of patients, but was only well tolerated in half of them. There may only be a few patients, however, who will clinically benefit from this rise in intraocular pressure. A better formulation or method of administration would be needed. RETINA 32: 742-747, 2012
AB - Purpose: To evaluate the effectiveness of 6 months treatment with ibopamine eye drops in raising the intraocular pressure in patients with therapy-resistant hypotony after vitreoretinal surgery for proliferative vitreoretinopathy secondary to rhegmatogenous retinal detachment or penetrating trauma. Methods: A 2% ibopamine eye drop was topically administered 3 times daily during 24 weeks. Results: Seventeen patients were included. Nine patients were able to continue their treatment up to 24 weeks; their mean intraocular pressure increase was 2.11 mmHg (SE, 0.56; 95% confidence interval, 0.96 to 3.23; P < 0.0005) in comparison with baseline values. Eight patients stopped using ibopamine before 24 weeks because of complains of follicular conjunctivitis or irritation without clinically observable conjunctivitis. In these patients a comparable increase in intraocular pressure was obs Conclusion: This study confirms that the use of topical ibopamine may result in a sustained increase in intraocular pressure of >2 mmHg in the majority of patients, but was only well tolerated in half of them. There may only be a few patients, however, who will clinically benefit from this rise in intraocular pressure. A better formulation or method of administration would be needed. RETINA 32: 742-747, 2012
U2 - 10.1097/IAE.0b013e3182265177
DO - 10.1097/IAE.0b013e3182265177
M3 - Article
C2 - 21909052
SN - 0275-004X
VL - 32
SP - 742
EP - 747
JO - Retina. The Journal of Retinal and Vitreous Diseases
JF - Retina. The Journal of Retinal and Vitreous Diseases
IS - 4
ER -